UNION CITY, Calif., Sept. 20 /PRNewswire/ — Questcor
Pharmaceuticals, Inc. (Nasdaq:
QCOR) announced today that it will present at the UBS Global
Life Sciences Conference on Wednesday, September 22, 2010 at The
Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief
Executive Officer, will discuss the Company’s business strategy and
historical financial performance at 3:30 p.m. Eastern Time.
Attendance at this conference is by invitation only. A live
audio and slides webcast of Questcor’s presentation may be accessed
through the Company’s website at www.questcor.com. An archived
replay of the presentation will be available after the live
presentation, and can also be accessed at www.questcor.com.
About Questcor
Questcor Pharmaceuticals is a biopharmaceutical company whose
products help patients with serious, difficult-to-treat medical
conditions. Questcor’s primary product is H.P. Acthar®
Gel (repository corticotropin injection). H.P. Acthar Gel
(“Acthar”) is an injectable drug that is approved for the treatment
of certain disorders, including the treatment of exacerbations
associated with multiple sclerosis (“MS”) and to induce a diuresis
or a remission of proteinuria in the nephrotic syndrome without
uremia of the idiopathic type or that is due to lupus
erythamatosus. In addition, Acthar is not indicated for, but is
used in treating patients with infantile spasms (“IS”), a rare form
of refractory childhood epilepsy, and opsoclonus myoclonus
syndrome, a rare autoimmune-related childhood neurological
disorder. For more information, please visit www.questcor.com.
‘/>”/>
SOURCE
